Summary The month of initial detection of tumour was recorded in 2,245 patients with breast cancer and correlated with survival over a follow-up period of 1.5-10 years. Women who initially detected their breast cancer in spring/summer had a significantly longer survival than those detecting their tumour at other times of the year. Overall, this relationship was independent of nodal status, tumour size and hormone receptor status. However, when patients were divided into groups the survival advantage was significantly associated with receptor status and age. Women aged > 50 years with ER-positive and PR-positive tumours who discovered their initial tumour in spring/summer had significantly better survival than those detecting their tumours at other times of the year. Survival was also longer in women aged < 50 years with receptor-negative tumours who initially found their tumours in spring/summer compared with the rest of the year. This study suggests that the season of first detection of a breast cancer relates significantly to the later behaviour of the tumour, and may reflect seasonal changes in hormone dependent growth.
A circannual rhythm of detection of breast cancer has been described by a number of workers in different countries, with a significantly increased frequency of tumour detection in spring/summer (Lee, 1967; Jacobsen & Janerich, 1977; Cohen et al., 1983; Hartveit et al., 1983; Mason et al., 1985; Kirkham et al., 1985) . This seasonal trend occurs predominantly in young or premenopausal women (Lee, 1967; Cohen et al., 1983; Mason et al., 1985; Kirkham et al., 1985) , and has been correlated with the presence of tumour hormone receptors (Jacobsen et al., 1977; Mason et al., 1985) .
Premenopausal women with breast cancer who find their tumours in the summer have a disease-free interval which is significantly longer than seen in patients who find their tumour in the winter (Mason et al., 1987) . In a preliminary report (Cohen, 1983) , women who detect their tumours in spring and summer have been shown to have better survival than those who detect their tumours in winter and autumn.
In the present study the relationship between season of tumour detection and overall survival has been assessed both overall and in patient subgroups divided according to age and tumour receptor status.
Methods
The Auckland Breast Cancer Study Group commenced recording clinical data on all new breast cancer cases in Auckland (1981 population 829,000) detected between 1976 and 1985 , with a total of 2,706 cases. Follow-up has been 1.5-10.5 years, with survival taken from the month when the cancer. was first detected by the patient. Of the 2,706 cases the month of first detection of tumour was recorded in 2,245. Three per cent have been lost to follow-up. Of (Holdaway, 1982 
Statistical methods
The relationship between survival and month of initial tumour detection was assessed in two ways. Initially 'periodic' terms were used in a proportional hazards regression to model the survival during the months of the year. To do this the hazard function was modelled using the following expression (Armitage et al., 1987) :
T(t,x) = T0(t)exp(3x) where Px represents the regression function, l,x, + P2x2 + * + &x, and To(t) is the time dependent part of the hazard. The x, and x2 terms were defined to be the periodic functions, cos (rt m/6) and sin (rcm/6) respectively, where m is month of year 1-12. In this way the significance of any periodic effect was determined together with the month of tumour detection associated with maximum survival. In addition survival was compared with season of tumour detection by dividing the year into categories of season according to Mason et al. (1985) . In this method the period of peak tumour detection (October to January, defined as 'spring/ summer') was compared with the remainder of the year and this comparison was performed using four other prognostic variables (nodal status, tumour size, ER status and PR status). 
Results
When the month of initial tumour detection was related to survival using the sinusoidal 'periodic' method a significant variation in survival was observed between months with detection in December being associated with longest survival (x2 = 7.42, d.f. = 2, P = 0.02). This is consistent with previous data where, calculating monthly detection rates of breast cancer using a two month moving average, the 4-month interval October to January was found to be the peak period for tumour detection (Mason et al., 1985) . Survival in patients detecting their tumours in October to January was thus compared with the remaining 8 months of the year and a significantly longer survival was found for those who detected their tumours during October to January, (X2 = 7.59, d.f. = 1, P = 0.006, odds ratio = 1.25, confidence interval= 1.07-1.47; Figure 1 ). In patient subgroups divided by receptor status, nodal status or age and analysed by the sinusoidal period method there was no significant variation in survival over the year. Therefore survival according to tumour detection in October to January versus February to September was studied in more detail.
The survival advantage for those detecting their tumour in
October to January was independent of nodal status, tumour size, oestrogen receptor status or progesterone receptor status when adjustment was made for each variable using the Cox's proportional hazards model. When all these variables were adjusted for, survival was still significantly related to season of initial tumour detection (P = 0.06; Table I ). Separation of groups by tumour receptor status showed a significant survival advantage for patients first detecting tumours in spring/summer compared with the remainder of the year in those with either ER positive or ER positive PR positive tumours. Overall no such survival difference was apparent for those with receptor negative tumours. However, these findings varied according to patient age. Women aged > 50 years with ER positive tumours had 13% improvement in survival at 5 years if the initial tumour was detected in spring/summer (X2 = 12.87, P = 0.0003, odds ratio = 2.04, confidence interval= 1.38-3.01; Figure 2 ). In premenopausal women with receptor positive tumours there was no significant relationship between season of detection and survival. However, in contrast to post-menopausal women, premenopausal patients had improved survival (26% at 5 years) if they had receptor negative tumours which were found initially in the spring/summer. The significance of this finding was, however, borderline (X2 = 3.64, P = 0.06, odds ratio = 2.3, confidence interval = 0.98-5.41; Figure 3 ). Survival of patients in different ER and PR subgroups is shown in Table II 
> 5 cm (47%) and patients with distant metastases at presentation (22%) compared with the group with known nodal status (11% and 6% respectively). In similar fashion the combined ER and PR receptor status was unknown in 50% (1,113 patients) of the original 2,245 patients, and in this subgroup season of detection also did not significantly predict length of survival (X2 = 2.05, P = 0.14, odds ratio = 1.17, confidence interval = 0.94-1.45), compared with 1,132 patients of known ER and PR status (x2 = 7.00, P = 0.008, odds ratio = 1.4, confidence interval = 1.09-1.80). However, for women aged < 50 years there was a trend for those who found their tumours in spring/summer to survive longer (n = 297, x2 = 2.9, P = 0.08, odds ratio = 1.46, confidence interval = 0.94-2.26). This is not so apparent for older women (X2 = 0.53, P = 0.46, odds ratio = 1.09, confidence interval = 0.86-1.37).
The characteristics of the patient subgroups of known or unknown receptor or nodal status are shown in Table III . Apart from significantly more large tumours in the group with unknown nodal status there was no significant differences in patient characteristics between these groups. Division by age < and > 50 years did not alter these findings.
In order to justify further the analysis of seasonal changes by comparing survival in patients discovering their tumours in October to January compared with the remainder of the year, the survival of women aged >50 years with ER positive tumours detecting their tumours in October to January was compared with those with tumour detection from February to May (decreasing light) and June to September (increasing light). The odds ratios were 3.54 and 3.34 respectively, with no apparent difference when comparing season of increasing or decreasing light. The seasonal variations thus do not appear to relate to photoperiod.
Discussion
This investigation suggests that the season of initial tumour detection is a significant specific prognostic variable in women with breast cancer. There is an overall survival advantage for women who initially detect their tumour in spring/early summer, and this effect is particularly pronounced in various subgroups. Thus, patients aged >.50 years with ER positive tumours detected initially in spring/ summer had a significant survival advantage of 13% at 5 years compared with those detecting tumours at other times of the year (Figure 2 ). In contrast, younger women aged < 50 years detecting their tumours in spring/summer had a survival advantage of 26% at 5 years if their tumours were receptor negative (Figure 3 ). The effect of season of detection appears to be a specific prognostic feature independent of tumour nodal or receptor status (Table I ). There was also a survival difference of 10% at 5 years in axillary node positive patients who detected their tumour in spring/summer. This difference was, however, reduced to 4% and was no longer significant in axillary node negative patients. This could reflect the greater number of deaths in node positive compared with node negative patients, and it may take a longer time for significant differences to emerge in the latter group. There appears to be a potential discrepancy between the observation that all women aged < 50 years who detected their tumours in spring/summer had a significantly improved survival compared with those detecting their tumours over the rest of the year, whereas no such advantage was seen for the subgroup of women aged < 50 years who had a known nodal status. However, 57% and 63% of women aged < 50 years with nodal status known were positive for ER and PR respectively, whereas in the group with unknown nodal status 50% were ER positive and 47% were PR positive. The influence of season of detection on survival in younger women was confined to ER negative PR negative women (Figure 3 ) and hence the comparative decrease in the proportion of receptor negative patients in the nodal status known group above may explain this discrepancy.
The survival advantage for women detecting their tumours in spring/summer was not seen in the subgroup of patients where receptor status was unknown. Even so, there were clear trends in the survival of these groups in the same direction as found in the overall group. Subgroup analysis suggests that oestrogen receptor status has an important influence on the interaction of survival and season of tumour detection and it is possible that failure to show significant results in the receptor unknown group could be due to an unusual distribution of receptor status in these patients.
The cause of seasonal variation in the frequency of detection of breast cancer and the means by which this influences patient survival remain uncertain. There is, however, evidence to support an association between breast cancer, tumour receptor status, melatonin production and/or pineal function which could be implicated in seasonal changes in tumour growth and detection. Thus, it has been shown that pre-and post-menopausal women with ER positive and PR positive tumours have a decreased nocturnal surge in plasma melatonin (Danforth et al., 1982 (Danforth et al., , 1985 . Tryptophan is a precursor of melatonin and urinary tryptophan metabolites are lower in women with ER negative tumours or ER positive PR negative tumours than in those with ER positive PR positive cancers (Lehrer et al., 1986) . Melatonin increases ER concentrations in human breast cancer cells in vitro (Danforth et al., 1983) , and physiological levels of melatonin inhibit the growth of ER positive cells in vitro (Hill, 1988) . Circannual changes in vitamin D and/or intracellular calcium levels could also contribute to seasonal effects in women with breast cancer.
The cause of the relationship between season of detection and survival is uncertain. In premenopausal women, an increase in oestrogen production in spring/summer (Kaupilla et al., 1987) may induce a seasonal acceleration of tumour growth leading to an increase in the rate of detection at this time, particularly in women with receptor positive tumours. Since these cancers are largely hormone-dependent, further tumour growth remains under hormonal regulation and overall survival is not significantly influenced by such seasonal factors. In contrast, post-menopausal women have no seasonal change in tumour growth and detection because ovarian activity has ceased. However, in these women, seasonal changes in other hormones such as increased melatonin or decreased prolactin could lead to some inhibition of tumour growth and so improve overall survival. It is more difficult to visualise how survival is influenced in young women with receptor negative tumours.
Regardless of the explanation for those findings it appears that season of detection of tumour is a hitherto unrecognised prognostic variable in patients with breast cancer. It provides information on prognosis additional to accepted indices such as nodal and receptor status. The biological mechanism by which season of detection relates to prognosis remains to be determined. However, it appears important to record the month of first detection of tumour in individual patients since this will obviously influence the analysis of results of treatment.
